236 related articles for article (PubMed ID: 36125673)
21. Effect of Dopaminergic Therapy on Impulse Control Disorders in Patients With a Prolactinoma.
Ozdeniz Varan E; Gurvit H
Cogn Behav Neurol; 2023 Mar; 36(1):1-8. PubMed ID: 36149404
[TBL] [Abstract][Full Text] [Related]
22. Treating prolactinomas with dopamine agonists: always worth the gamble?
Noronha S; Stokes V; Karavitaki N; Grossman A
Endocrine; 2016 Feb; 51(2):205-10. PubMed ID: 26336835
[TBL] [Abstract][Full Text] [Related]
23. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
24. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.
Zeng Y; Huang Q; Zou Y; Tan J; Zhou W; Li M
Front Endocrinol (Lausanne); 2023; 14():1027905. PubMed ID: 36761195
[TBL] [Abstract][Full Text] [Related]
26. Prolactin excess: treatment and toxicity.
Gillam MP; Fideleff H; Boquete HR; Molitch ME
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():108-14. PubMed ID: 16456489
[TBL] [Abstract][Full Text] [Related]
27. A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma.
Sahin S; Sudutan T; Kavla Y; Durcan E; Özogul YY; Poyraz BC; Sayitoglu M; Ozkaya HM; Kadioglu P
J Clin Endocrinol Metab; 2023 May; 108(6):e275-e282. PubMed ID: 36494095
[TBL] [Abstract][Full Text] [Related]
28. Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions.
Ramirez-Zamora A; Gee L; Boyd J; Biller J
Expert Rev Neurother; 2016; 16(4):389-99. PubMed ID: 26923084
[TBL] [Abstract][Full Text] [Related]
29. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.
Voon V; Schoerling A; Wenzel S; Ekanayake V; Reiff J; Trenkwalder C; Sixel-Döring F
BMC Neurol; 2011 Sep; 11():117. PubMed ID: 21955669
[TBL] [Abstract][Full Text] [Related]
30. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
31. Dopamine and impulse control disorders in Parkinson's disease.
Weintraub D
Ann Neurol; 2008 Dec; 64 Suppl 2(Suppl 2):S93-100. PubMed ID: 19127573
[TBL] [Abstract][Full Text] [Related]
32. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
33. Clinical spectrum of impulse control disorders in Parkinson's disease.
Weintraub D; David AS; Evans AH; Grant JE; Stacy M
Mov Disord; 2015 Feb; 30(2):121-7. PubMed ID: 25370355
[TBL] [Abstract][Full Text] [Related]
34. Impulse control disorders in Parkinson's disease.
Weintraub D; Potenza MN
Curr Neurol Neurosci Rep; 2006 Jul; 6(4):302-6. PubMed ID: 16822350
[TBL] [Abstract][Full Text] [Related]
35. Drug treatment of hyperprolactinemia.
Chanson P; Borson-Chazot F; Chabre O; Estour B
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):113-7. PubMed ID: 17532288
[TBL] [Abstract][Full Text] [Related]
36. Quinagolide--a valuable treatment option for hyperprolactinaemia.
Barlier A; Jaquet P
Eur J Endocrinol; 2006 Feb; 154(2):187-95. PubMed ID: 16452531
[TBL] [Abstract][Full Text] [Related]
37. Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management.
Wu K; Politis M; Piccini P
Postgrad Med J; 2009 Nov; 85(1009):590-6. PubMed ID: 19892894
[TBL] [Abstract][Full Text] [Related]
38. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
Webster J
Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
[TBL] [Abstract][Full Text] [Related]
39. Impulse control and related disorders in Parkinson's disease.
Weintraub D; Nirenberg MJ
Neurodegener Dis; 2013; 11(2):63-71. PubMed ID: 23038208
[TBL] [Abstract][Full Text] [Related]
40. The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis.
Zou Y; Li D; Gu J; Chen S; Wen X; Dong J; Jiang X
BMC Endocr Disord; 2021 Nov; 21(1):225. PubMed ID: 34774043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
